Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02495246
Other study ID # EBL05
Secondary ID
Status Completed
Phase Phase 1
First received June 18, 2015
Last updated April 10, 2018
Start date September 21, 2015
Est. completion date August 22, 2017

Study information

Verified date April 2018
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO-Z and Ad26.ZEBOV. Four groups of volunteers will be vaccinated with both vaccines one after the other in a prime/boost regimen.

All ChAd3-EBO-Z doses are 1x10^11 vp and all Ad26.ZEBOV doses are 5x10^10 vp.

Group 1 will receive a ChAd3-EBO-Z priming vaccine and an Ad26.ZEBOV boosting vaccine 28 days later.

Group 2 will receive an Ad26.ZEBOV priming vaccine and a ChAd3-EBO-Z boosting vaccine 28 days later.

Group 3 will receive a ChAd3-EBO-Z priming vaccine and an Ad26.ZEBOV boosting vaccine 56 days later.

Group 4 will receive an Ad26.ZEBOV priming vaccine and a ChAd3-EBO-Z boosting vaccine 56 days later.

The study will assess the safety of the vaccinations, and the immune responses to vaccination. Immune responses are measured by tests on blood samples.

The ChAd3-EBO-Z and Ad26.ZEBOV vaccines are called viral vectored vaccines. They are made from viruses which are modified so that they cannot multiply. The viruses have extra DNA in them so that after injection, the body makes Ebola proteins (but Ebola does not develop), so that the immune system builds a response to Ebola without having been infected by it.

Healthy volunteers will be recruited in Oxford and London, England. The study will be co-funded by GSK Biologicals and Crucell Holland BV.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date August 22, 2017
Est. primary completion date August 22, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy adults aged 18 to 50 years

- Able and willing (in the Investigator's opinion) to comply with all study requirements

- Willing to allow the investigators to discuss the volunteer's medical history with their GP

- For females only, willingness to practice continuous effective contraception (see section 6.3.3) during the study and a negative pregnancy test on the day(s) of screening and vaccination

- Agreement to refrain from blood donation during the course of the study

- Provide written informed consent

Exclusion Criteria:

- Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period

- Prior receipt of an investigational Ebola or Marburg vaccine, a chimpanzee adenovirus, or any other investigational vaccine likely to impact on interpretation of the trial data

- Receipt of any live, attenuated vaccine within 28 days prior to enrolment

- Receipt of any subunit or killed vaccine within 14 days prior to enrolment

- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate

- Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)

- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, (e.g. egg products) including urticaria, respiratory difficulty or abdominal pain

- Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.

- Any history of anaphylaxis in reaction to vaccination

- Pregnancy, lactation or willingness/intention to become pregnant during the study

- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)

- History of serious psychiatric condition

- Poorly controlled asthma or thyroid disease

- Seizure in the past 3 years or treatment for seizure disorder in the past 3 years

- Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture

- Any other serious chronic illness requiring hospital specialist supervision

- Current anti-tuberculosis prophylaxis or therapy

- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week

- Suspected or known injecting drug abuse in the 5 years preceding enrolment

- Seropositive for hepatitis B surface antigen (HBsAg)

- Seropositive for hepatitis C virus (antibodies to HCV)

- Travel to a Ebola or Marburg endemic region during the study period or within the previous six months

- Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis (see Appendix A and Appendix B)

- Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

- Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate

Study Design


Intervention

Biological:
ChAd3-EBO-Z

Ad26.ZEBOV


Locations

Country Name City State
United Kingdom Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford Oxford Oxfordshire

Sponsors (1)

Lead Sponsor Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of administration of ChAd3-EBO-Z and Ad26.ZEBOV 28 days later. This will be done by recording the number of participants who experience adverse events and the severity of any adverse events. 17 weeks
Primary Safety and tolerability of administration of Ad26.ZEBOV and ChAd3-EBO-Z 28 days later. This will be done by recording the number of participants who experience adverse events and the severity of any adverse events. 17 weeks
Primary Safety and tolerability of administration of ChAd3-EBO-Z and Ad26.ZEBOV 56 days later. This will be done by recording the number of participants who experience adverse events and the severity of any adverse events. 21 weeks
Primary Safety and tolerability of administration of Ad26.ZEBOV and ChAd3-EBO-Z 56 days later. This will be done by recording the number of participants who experience adverse events and the severity of any adverse events. 21 weeks
See also
  Status Clinical Trial Phase
Completed NCT00374309 - Experimental Vaccine for Prevention of Ebola Virus Infection Phase 1
Completed NCT03098862 - PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Completed NCT02509494 - Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo Phase 3
Recruiting NCT06093646 - Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda N/A
Completed NCT04906629 - INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees Phase 1
Completed NCT05064956 - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) Phase 2
Not yet recruiting NCT06126822 - Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC Phase 3
Withdrawn NCT04268966 - An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola Phase 2
Completed NCT02267109 - Phase 1 Trial of Ebola Vaccine in Mali Phase 1
Not yet recruiting NCT04822376 - Prophylaxis Vaccine Antibodies Ebola Phase 2
Recruiting NCT02333578 - Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment N/A
Completed NCT02662855 - Efficacy of Favipiravir Against Severe Ebola Virus Disease Phase 2
Active, not recruiting NCT04152486 - Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC Phase 3
Terminated NCT04250168 - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Completed NCT03161366 - Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Phase 3
Completed NCT03140774 - Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
Suspended NCT03462004 - Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein Phase 1
Active, not recruiting NCT02876328 - Partnership for Research on Ebola VACcinations Phase 2
Not yet recruiting NCT05202288 - Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Phase 2
Completed NCT02401373 - A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. Phase 1